155 related articles for article (PubMed ID: 25424440)
1. Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease.
Zschiedrich S; Budde K; Walz G
Clin Exp Nephrol; 2015 Aug; 19(4):757-8. PubMed ID: 25424440
[No Abstract] [Full Text] [Related]
2. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.
Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP
BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206
[TBL] [Abstract][Full Text] [Related]
3. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
[TBL] [Abstract][Full Text] [Related]
4. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
[TBL] [Abstract][Full Text] [Related]
5. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
[TBL] [Abstract][Full Text] [Related]
6. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
van Keimpema L; Nevens F; Vanslembrouck R; van Oijen MG; Hoffmann AL; Dekker HM; de Man RA; Drenth JP
Gastroenterology; 2009 Nov; 137(5):1661-8.e1-2. PubMed ID: 19646443
[TBL] [Abstract][Full Text] [Related]
7. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.
Seliger SL; Abebe KZ; Hallows KR; Miskulin DC; Perrone RD; Watnick T; Bae KT
Am J Nephrol; 2018; 47(5):352-360. PubMed ID: 29779024
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin, estrogen, and polycystic liver disease.
Everson GT; Helmke SM
Gastroenterology; 2013 Aug; 145(2):279-82. PubMed ID: 23806538
[No Abstract] [Full Text] [Related]
10. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP
Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials.
Neijenhuis MK; Gevers TJ; Nevens F; Hogan MC; Torres VE; Kievit W; Drenth JP
Aliment Pharmacol Ther; 2015 Sep; 42(5):591-8. PubMed ID: 26129925
[TBL] [Abstract][Full Text] [Related]
12. Ciprofloxacin penetration into infected hepatic cysts in autosomal dominant polycystic kidney disease: a case report.
Bernts LHP; Wallenburg E; de Jonge HJM; Schaap B; Kusters R; Overtoom TTC; Brüggemann RJM; Drenth JPH; Lantinga MA
J Antimicrob Chemother; 2019 Mar; 74(3):829-830. PubMed ID: 30452619
[No Abstract] [Full Text] [Related]
13. Massive cystic liver in a patient with autosomal dominant polycystic kidney disease.
Panchabhai TS; Aronoff GR
South Med J; 2010 Jul; 103(7):718-20. PubMed ID: 20531034
[No Abstract] [Full Text] [Related]
14. Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.
Hogan MC; Masyuk T; Bergstralh E; Li B; Kremers WK; Vaughan LE; Ihrke A; Severson AL; Irazabal MV; Glockner J; LaRusso NF; Torres VE
Mayo Clin Proc; 2015 Aug; 90(8):1030-7. PubMed ID: 26166166
[TBL] [Abstract][Full Text] [Related]
15. Liver cysts in patients with autosomal dominant polycystic kidney disease.
Gandhi RM; Patil RA; Mehta NP; Thomas C
J Assoc Physicians India; 1993 Sep; 41(9):590-1. PubMed ID: 8307917
[No Abstract] [Full Text] [Related]
16. The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials.
Garofalo C; Capuano I; Pennino L; De Gregorio I; Riccio E; Provenzano M; Crocetto F; Buonanno P; Pandolfo SD; Andreucci M; Pisani A
Sci Rep; 2021 Dec; 11(1):23500. PubMed ID: 34873228
[TBL] [Abstract][Full Text] [Related]
17. KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Polycystic Liver Disease.
Savige J; Mallett A; Tunnicliffe DJ; Rangan GK
Semin Nephrol; 2015 Nov; 35(6):618-622.e5. PubMed ID: 26718168
[No Abstract] [Full Text] [Related]
18. Therapeutic challenge of ERCP for biliary decompression in a patient with autosomal dominant polycystic kidney disease and polycystic liver disease and pancreaticoduodenectomy anatomy.
Figurelli HG; Laurie T; Chi KD
Gastrointest Endosc; 2012 Apr; 75(4):896-7; discussion 898. PubMed ID: 22281112
[No Abstract] [Full Text] [Related]
19. Multiple fluid-filled liver cysts presenting as acute pancreatitis in a patient with known autosomal dominant polycystic kidney disease.
Thyagarajan B; Ghatage P; Alagusundaramoorthy SS; Patel S
BMJ Case Rep; 2016 Jul; 2016():. PubMed ID: 27435849
[No Abstract] [Full Text] [Related]
20. Massive liver polycystic disease in a kidney transplanted patient.
Esposito P; Bosio F; Rampino T; Dal Canton A
Dig Liver Dis; 2012 Jul; 44(7):623. PubMed ID: 22444522
[No Abstract] [Full Text] [Related]
[Next] [New Search]
